Prof Thierry André speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about the final overall survival results for the KN177 study.

He explains that the phase III study looked at pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

Prof André says that the data confirms pembrolizumab as a new standard-of-care in the first-line for these patients.

Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php

свернуть